TY - JOUR
T1 - A retrospective study of amitriptyline in youth with autism spectrum disorders
AU - Bhatti, Irfan
AU - Thome, Andrew
AU - Smith, Patricia Oxler
AU - Cook-Wiens, Galen
AU - Yeh, Hung Wen
AU - Gaffney, Gary R.
AU - Hellings, Jessica A.
N1 - Funding Information:
Acknowledgments This work was supported by a grant from the Kansas Center for Autism Research and Training (K-CART).
Funding Information:
Conflict of interest Dr. Hellings has non-reimbursed collaboration with Roche. She has received prior study drug funding from Abbott Laboratories Inc, Janssen Pharmaceuticals, NIMH and NICHD. Dr. Gaffney has grants/contracts with Merck, NIDA, NHTSA and the Department of Defense. The authors wish to thank Ms. Carla J. Meister for her technical assistance in preparation and submission of this manuscript. No other authors have conflicts of interest.
PY - 2013/5
Y1 - 2013/5
N2 - We performed a retrospective chart review of 50 youths with Autism Spectrum Disorder (ASD), prescribed amitriptyline (AMI) for hyperactivity and impulsivity. Data was systematically extracted from 50 outpatient clinic charts, including AMI treatment duration, dose, trough levels and adverse events. Mean age was 9.4 years (4.6-17.9); 40 were males and 10 females. 30 % had failed atomoxetine and 40 % had failed ≥3 ADHD medications. Mean dose was 1.3 ± 0.6 mg/kg/day, mean trough level 114.1 ± 50.5 ng/ml, mean duration 3.4 years. Clinical Global Impressions Scale-Improvement (CGI-I) was ≤2 in 60 % of patients at the final visit, and in 82 % of patients for at least 50 % of follow-ups. Cautious use of low dose AMI shows promise for treatment-resistant youth with ASD accompanied by hyperactivity, impulsivity, aggression and self injury.
AB - We performed a retrospective chart review of 50 youths with Autism Spectrum Disorder (ASD), prescribed amitriptyline (AMI) for hyperactivity and impulsivity. Data was systematically extracted from 50 outpatient clinic charts, including AMI treatment duration, dose, trough levels and adverse events. Mean age was 9.4 years (4.6-17.9); 40 were males and 10 females. 30 % had failed atomoxetine and 40 % had failed ≥3 ADHD medications. Mean dose was 1.3 ± 0.6 mg/kg/day, mean trough level 114.1 ± 50.5 ng/ml, mean duration 3.4 years. Clinical Global Impressions Scale-Improvement (CGI-I) was ≤2 in 60 % of patients at the final visit, and in 82 % of patients for at least 50 % of follow-ups. Cautious use of low dose AMI shows promise for treatment-resistant youth with ASD accompanied by hyperactivity, impulsivity, aggression and self injury.
KW - Amitriptyline
KW - Autism Spectrum Disorders
KW - Hyperactivity
KW - Impulsivity
UR - http://www.scopus.com/inward/record.url?scp=84877925208&partnerID=8YFLogxK
U2 - 10.1007/s10803-012-1647-0
DO - 10.1007/s10803-012-1647-0
M3 - Article
C2 - 23135317
AN - SCOPUS:84877925208
SN - 0162-3257
VL - 43
SP - 1017
EP - 1027
JO - Journal of autism and developmental disorders
JF - Journal of autism and developmental disorders
IS - 5
ER -